PHILADELPHIA, April 7, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today reported that it is accelerating a strategic initiative to explore the therapeutic potential for its experimental therapeutic Ampligen(r) as an adjuvant to vaccines for HIV/AIDS, and for avian influenza (“bird flu”). The stepped-up initiatives follow recent disappointments by other vaccines targeting HIV, as well as new reports in Indonesia that avian influenza now poses an increased threat due to recent mutations of the virus.
